Anlotinib is known to target various RTKs, including VEGFR1-3, PDGFRα-β, c-KIT and FGFR1-4, demonstrating high efficacy with substantial suppression of cell proliferation in multiple cancers.29–33 To investigate the potential antitumor efficacy of anlotinib monotherapy in KRAS-mutant NSCLC, we first performed a retrospective analysis of patients harboring various KRAS mutations enrolled in the ALTER-0303 study,31 a phase III clinical trial (NCT02388919) evaluating the efficacy of anlotinib in the third-line or later treatment of advanced NSCLC. Here, FGFR1 is linked to non-small cell lung carcinoma.